BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 33502905)

  • 1. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
    Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
    J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
    Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
    Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
    Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain.
    Trigo-Vicente C; Gimeno-Ballester V; López-Del Val A
    Eur J Hosp Pharm; 2020 Nov; 27(6):355-360. PubMed ID: 33097619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
    Hernandez L; Kuwabara H; Shah A; Yamabe K; Burnett H; Fahrbach K; Koufopoulou M; Iwakiri R
    Pharmacoeconomics; 2020 Jan; 38(1):69-84. PubMed ID: 31552601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.
    Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC
    Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
    Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
    Wu B; Wang Z; Zhang Q
    Inflamm Bowel Dis; 2018 Oct; 24(11):2291-2302. PubMed ID: 29718241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
    Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece.
    Vellopoulou K; Stefanou G; Tzanetakos C; Boubouchairopoulou N; Nakou M; Gourzoulidis G; Kourlaba G
    Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):325-333. PubMed ID: 32976189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
    Aliyev ER; Hay JW; Hwang C
    Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia.
    Gil F; Juliao-Baños F; Amador L; Castano N; Reyes JM
    Pharmacoecon Open; 2022 Nov; 6(6):837-846. PubMed ID: 35943702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis.
    Schultz BG; Diakite I; Carter JA; Snedecor SJ; Turpin R
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1592-1600. PubMed ID: 34714104
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada.
    Fenu E; Lukyanov V; Acs A; Radu X; Stypa S; Fischer A; Marshall JK; Oppe M
    Pharmacoecon Open; 2022 Jul; 6(4):519-537. PubMed ID: 35474178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.
    Singh S; Murad MH; Fumery M; Dulai PS; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2179-2191.e6. PubMed ID: 31945470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
    Bonovas S; Lytras T; Nikolopoulos G; Peyrin-Biroulet L; Danese S
    Aliment Pharmacol Ther; 2018 Feb; 47(4):454-465. PubMed ID: 29205421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov Model.
    Mahmoud R; van Lieshout C; Frederix GWJ; Jharap B; Oldenburg B
    J Crohns Colitis; 2021 May; 15(5):709-718. PubMed ID: 33125060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
    Shaffer SR; Huang E; Patel S; Rubin DT
    Am J Gastroenterol; 2021 Jan; 116(1):125-133. PubMed ID: 32947317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.